MedTrace Logo

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

NCT01129362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1195

Last updated 2022-04-25

No results posted yet for this study

Summary

The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease.

Primary Objective:

To determine the rates and relative risk of pertussis disease among Surveillance Population members who have received Pentacel vaccine or another pertussis vaccine.

Conditions

  • Pertussis

Interventions

BIOLOGICAL

Pentacel® (DTaP-IPV/Hib)

0.5 mL dose, Intramuscular

BIOLOGICAL

Other Pertussis Vaccines

0.5 mL, Intramuscular

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur Inc.

Eligibility

Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-08
Primary Completion
2014-12-30
Completion
2014-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129362 on ClinicalTrials.gov